Using interactive voice response to improve disease management and compliance with acute coronary syndrome best practice guidelines: A randomized controlled trial.

BACKGROUND: There is evidence from large clinical trials that compliance with standardized best practice guidelines (BPGs) improves survival of acute coronary syndrome (ACS) patients. However, their application is often suboptimal. PURPOSE: In this study, the researchers evaluated whether the use of an interactive voice response (IVR) follow-up system improved ACS BPG compliance. METHOD: This was a single-centre randomized control trial (RCT) of 1,608 patients (IVR=803; usual care=805). The IVR group received five automated calls in 12 months. The primary composite outcome was increased medication compliance and decreased adverse events. RESULTS: A significant improvement of 60% in the IVR group for the primary composite outcome was found (RR 1.60, 95% CI: 1.29 to 2.00, p <0.001). There was significant improvement in medication compliance (p <0.001) and decrease in unplanned medical visits (p = 0.023). At one year, the majority of patients ( 85%) responded positively to using the system again. Follow-up by IVR produced positive outcomes in ACS patients.

Utilization of home telemonitoring in patients 75 years of age and over with complex heart failure.

We conducted a chart review on all patients who had received home telemonitoring after an admission for heart failure at the University of Ottawa Heart Institute. During a 5 year period (2005-2009) a total of 645 patients had home monitoring. A total of 594 patients met the inclusion criteria for the study and were divided into two groups: Group 1 (<75 years of age) contained 350 patients and Group 2 (≥75 years of age) contained 244 patients. There was no significant difference between the groups in the mean duration of follow-up by the telemonitoring team: it was 126.5 days in Group 1 and 125.4 days in Group 2 (P = 0.89). There were no significant differences between the groups in the number of times that titration of diuretic medications occurred, the number of times that titration of cardiac medications occurred, the number of interventions for abnormal vital signs or the number of times that patients were called by the telemonitoring staff. Emergency room visits, hospitalizations and the number of deaths were also not different between two groups. Thus in the telemonitoring programme, the pattern of usage by older patients was similar to that of the younger ones. Based on the present study, the elderly do not require more resources nor do they require them for longer.

Using technology to create a medication safety net for cardiac surgery patients: a nurse-led randomized control trial.

PURPOSE: Interactive voice response (IVR) technology was used to increase medication compliance and reduce adverse events (hospitalization and emergency visits) in post-cardiac surgery patients. METHOD: Patients randomized to intervention received 11 automated IVR calls in the six months after discharge. A total of 331 patients (164 IVR, 167 usual care) participated. RESULTS: Findings showed significant differences in the IVR group for the primary composite outcome of compliance and adverse events (relative risk (RR] and 95% confidence interval [CI]: 0.60 [0.37, 0.96), p = 0.041) and the secondary outcome of medication compliance (RR: 0.34 (0.20, 0.56), p < 0.0001). There was no significant impact on emergency room visits (RR: 1.04 (0.63, 1.73J) and hospitalization (RR: 0.77 [0.41, 1.45]). Most patients (93%) preferred IVR follow-up to no follow-up.

Telehome monitoring in patients with cardiac disease who are at high risk of readmission.

Patients with chronic conditions are heavy users of the health care system. There are opportunities for significant savings and improvements to patient care if patients can be maintained in their homes. A randomized control trial tested the impact of 3 months of telehome monitoring on hospital readmission, quality of life, and functional status in patients with heart failure or angina. The intervention consisted of video conferencing and phone line transmission of weight, blood pressure, and electrocardiograms. Telehome monitoring significantly reduced the number of hospital readmissions and days spent in the hospital for patients with angina and improved quality of life and functional status in patients with heart failure or angina. Patients found the technology easy to use and expressed high levels of satisfaction. Telehealth technologies are a viable means of providing home monitoring to patients with heart disease at high risk of hospital readmission to improve their self-care abilities.

Effect of bisoprolol on right ventricular function and brain natriuretic peptide in patients with heart failure.

Beta-blocker use improves left ventricular ejection fraction (LVEF) in patients with heart failure. A similar effect of b blockers on right ventricular function has been proposed, although the effect of bisoprolol, a highly selective b-1 blocker, on right ventricular function has not been assessed. This study investigated the short-term effect of bisoprolol on right ventricular function in chronic heart failure patients. A cohort of 30 heart failure patients who were not taking b blockers at baseline was studied prospectively. Right ventricular ejection fraction (RVEF) and LVEF were measured at both baseline and 4 months by radionuclide angiography. Bisoprolol was up-titrated during four monthly visits by a preestablished protocol to a target dose of 10 mg/d. The dose of vasodilators was not changed. Quality of life and brain natriuretic peptide level were assessed. Mean age was 62.7+/-14.3 years. Baseline RVEF was 30.7%+/-6.3% and baseline LVEF was 21.7%+/-9.4%. Mean bisoprolol dose reached was 5.3+/-3.9 mg daily. At 4 months, RVEF significantly increased by 7.1% (95% confidence interval, 3.9-10.2; p=0.0001) and LVEF also increased significantly by 7.9% (95% confidence interval, 4.0%-11.9%; p=0.0003). Quality-of-life score improved from 42.8 to 30.8 (p=0.047). No correlation was found between brain natriuretic peptide levels and RVEF. Bisoprolol treatment for 4 months resulted in a significant improvement of RVEF, which paralleled the improvement of LVEF.

Ventricular assist devices as a bridge to cardiac transplantation: the Ottawa experience.

This article reports our experience with ventricular assist devices (VADs) as a bridge to cardiac transplantation. From 1991 to 2003, a total of 42 patients received a Thoratec VAD (Thoratec Laboratories Corporation Inc., Pleasanton, CA, U.S.A.) (Group T) and 12 patients received a Novacor VAD (WorldHeart Corporation, Ottawa, Canada) (Group N). Thirty Thoratec patients were transplanted compared to six in the Novacor group. Four more Novacor patients are still supported. Of the transplanted patients, 87% survived to hospital discharge in Group T and 67% in Group N. Infections affected 29% and 50% of Group T patients during support and post-transplantation, respectively, compared to 25% and 0%, respectively, in Group N. Neurologic complications affected 33% of patients in each group during support. Reopening rates for bleeding during support were 45% and 42% in Groups T and N, respectively. There were no significant differences in outcomes between the two groups. Our study demonstrated the effectiveness of VADs in bridging mortally ill cardiac patients to successful heart transplantation.

Improved early survival with the total artificial heart.

We report our experience with the total artificial heart (TAH) to determine if outcomes have improved. Thirty-one patients received the TAH as a bridge to transplant and were divided into the two groups A (eighteen implanted in the first eight years) and B (thirteen implanted in the last eight years). Changes in management included immediate sternal closure, early extubation, delayed transplant listing, early rehabilitation, and measurement of preformed antibodies. The infection rate in B was lower than in A, both during support (31% versus 39%) and following transplant (38% versus 72%), and rejection was lower in B than in A (0% versus 44%). There was no difference in neurological events between groups; however, reopening was more frequent in B (61% versus 28%). Hospital survival increased from 61% in A to 85% in B; however, this was not statistically significant. We hypothesize that this improvement was likely due to changes in patient management.

Heart transplantation at the Ottawa heart institute: comparison with Canadian and international results.

Heart transplantation has been carried out in 340 patients in Ottawa, including seventy-one who required mechanical circulatory support as a bridge to transplant. Survival in Ottawa was compared with other Canadian centers based on data from the Canadian Organ Replacement Register up to the year 2000 and with the International Society of Heart and Lung Transplantation (ISHLT) registry 2001. For survival analysis, the number of adult patients at risk at year 0 was 303 (87 transplanted from 1985 to 1990, 105 from 1990 to 1994, and 111 from 1995 to 2000). The Statistical Analysis System (SAS) life test procedure was used. Survival was not adjusted for comorbidities or heart failure class. For the year of transplant 1985-1989, one-, five-, and ten-year patient survival in Ottawa was 83%, 70%, and 60%, respectively, compared to 82%, 71%, and 54%, respectively, for Canada (Wilcoxon test, P = 0.71), and compared to one- and five-year survival for ISHLT from 1980 to 1987 at 76% and 60%, respectively. For 1990-1994, one-, five-, and ten-year patient survival in Ottawa was 88%, 81%, and 74%, respectively, compared to 80%, 71%, and 61%, respectively, for Canada (P = 0.05), and compared to one- and five-year survival for ISHLT from 1998 to 1992 at 80% and 68%, respectively. For 1995-2000, one- and five-year patient survival in Ottawa was 90% and 82%, respectively, compared to 85% and 76%, respectively, for Canada (P = 0.09), and compared to one- and five-year survival for ISHLT from 1993 to 1996 at 82% and 68%, respectively. Survival after heart transplantation in Ottawa compares favorably with Canadian and international data.

Mechanical circulatory support for adolescent patients: the Ottawa Heart Institute experience.

BACKGROUND: Mechanical circulatory support devices may be used for patients with end-stage heart failure for bridging either to cardiac transplant or to recovery of the native heart. While less common in adolescents, fulminant heart failure may be rapidly fatal in these patients unless circulatory support can be instituted. OBJECTIVES: To assess the outcomes and the utility of mechanical circulatory assist devices for children. METHODS: A retrospective review of pediatric patients (18 years of age or younger) who underwent circulatory support at the Ottawa Heart Institute, Ottawa, Ontario, from 1992 to 2001 was performed using chart audits. RESULTS: Seven patients (four boys, three girls) with a mean age of 14.9 +/- 0.9 years were supported with Thoratec ventricular assist devices (n=6) or a CardioWest total artificial heart (n=1). Preoperatively, the cardiac index was 1.64 +/- 0.2 L/min/m2 on one or two inotropes with ejection fractions of 11 +/- 2.2%. Mean duration of circulatory support was 59.3 +/- 17.2 days with a hospital length of stay of 89.6 +/- 12.8 days. All seven patients underwent successful transplantation and were discharged home. CONCLUSIONS: Pediatric patients with fulminant heart failure may be bridged to cardiac transplant successfully with mechanical circulatory support devices.

Giant cell myocarditis: clinical presentation, bridge to transplantation with mechanical circulatory support, and long-term outcome.

BACKGROUND: The multicenter Giant Cell Myocarditis Registry recorded 64 cases from 36 centers before 1996. The median transplant-free survival of 30 patients without immunosuppression was 3 months. Of 34 patients who received heart transplantations, 9 experienced recurrence of giant cell myocarditis in their transplanted hearts and 1 patient died. METHODS: We reviewed our experience in 340 heart transplantations since 1984. Unexpected giant cell myocarditis was found in the explanted hearts of 7 patients (6 men and 1 female, aged 18-65 years). RESULTS: The duration from the onset of symptoms to assist-device implant or transplantation ranged from 11 days to 9 years, whereas the time interval from referral or deterioration ranged from 2 days to 4 months. Four patients required mechanical circulatory support before surgery (total artificial hearts in 2 and left ventricular assist devices in 2), and 3 patients required inotropic drugs. Six patients are alive with no sign of recurrent giant cell myocarditis at 12 to 113 months after surgery. One patient died suddenly 75 months after surgery, and autopsy showed severe graft vascular disease with no recurrence of giant cell myocarditis. Surveillance, right ventricular endomyocardial biopsy specimens showed recurrent asymptomatic giant cell myocarditis in 3 patients at 5 to 13 months after surgery, and found recurrence in 1 patient 30 months after surgery. This patient received augmented immunosuppression. CONCLUSIONS: Giant cell myocarditis often is not diagnosed before transplantation. It can present as dilated cardiomyopathy with late deterioration, or it can present with rapid hemodynamic deterioration. In our experience, these patients can be bridged successfully to transplant with mechanical circulatory assist. Giant cell myocarditis may recur after transplantation but may respond to augmented immunosuppression.